Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) Bundle
From its founding as Yantai Dongcheng Biochemical Co., Ltd. in 1998 to a 2012 rebrand and Shenzhen Stock Exchange listing (stock code 002675, May 2012), Yantai Dongcheng Pharmaceutical Group has grown into a vertically integrated pharma player with more than 40 subsidiaries and R&D branches in Beijing, Shanghai and Nanjing, employing over 2,000 people; today it exports over 90% of its product mix-APIs, finished dosage forms, nuclide drugs and health products-to 40+ countries, leverages a vertically integrated heparin full industry chain and GMP certifications (including Korea FDA and EDQM) to secure quality, invests about 8-10% of revenue annually in R&D, and, with a market capitalization near 11.89 billion CNY (Dec 2025) and daily trading volumes exceeding 11 million shares, sits at the intersection of robust export-driven manufacturing, long-term international partnerships and an innovation-led growth strategy that fuels its diversified revenue streams.
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ): Intro
History- Founded in 1998 as Yantai Dongcheng Biochemical Co., Ltd.; rebranded in 2012 to Yantai Dongcheng Pharmaceutical Group Co., Ltd. to reflect diversified operations.
- Listed on the Shenzhen Stock Exchange in May 2012 under stock code 002675.
- Two-plus decades of evolution from a biochemical API manufacturer to a multi‑sector pharmaceutical group.
| Year | Event | Significance |
|---|---|---|
| 1998 | Company established as Yantai Dongcheng Biochemical Co., Ltd. | Founding and initial focus on biochemical APIs |
| 2012 | Rebranded to Yantai Dongcheng Pharmaceutical Group Co., Ltd.; listed on SZSE (002675) | Broadened corporate scope and accessed public capital markets |
| 2012-Present | Expansion into finished dosage forms, nuclide drugs, health products; R&D branches opened | Vertical integration and international expansion |
- Publicly listed company (Shenzhen Stock Exchange, 002675.SZ) with institutional and retail shareholders.
- Operates through a network of over 40 subsidiaries, including:
- Yantai Dongcheng Beifang Pharmaceutical Co., Ltd.
- Yantai Dongcheng Dayang Pharmaceuticals Co., Ltd.
- Linyi Dongcheng Dongyuan Biological Engineering Co., Ltd.
- R&D presence in Beijing, Shanghai, and Nanjing; workforce exceeding 2,000 employees.
- Export-oriented: as a leading biochemical API producer in China, the company exports over 90% of API output to more than 40 countries and regions worldwide.
- Corporate mission emphasizes innovation in pharmaceutical ingredients and downstream products while serving global healthcare markets.
- For detailed corporate mission, vision, and values, see: Mission Statement, Vision, & Core Values (2026) of Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
- Biochemical APIs - core historical competency; high-volume production, global export focus (over 90% exported).
- Finished dosage forms - downstream integration to capture higher-margin formulations and finished products for domestic and selected export markets.
- Nuclide drugs - specialty radiopharmaceuticals and related products targeting niche clinical applications; strategic growth area requiring high regulatory compliance and technical capability.
- Health products - consumer-facing supplements and wellness products leveraging manufacturing and distribution networks.
- Primary revenue drivers:
- Bulk API sales (dominated by export volumes).
- Finished product sales (domestic and export customers, branded and OEM/contract manufacturing).
- Nuclide drug production and specialized services (higher-margin but lower-volume).
- Health product retail/wholesale channels.
- Vertical integration (API → formulation → finished-product) captures value across the supply chain and reduces raw-material dependency.
- R&D and regulatory capabilities enable product upgrades, new indications, and entry into regulated export markets.
| Metric | Reported / Stated Value |
|---|---|
| Founding year | 1998 |
| Listing | Shenzhen Stock Exchange, May 2012 (002675.SZ) |
| Subsidiaries | Over 40 |
| Employees | More than 2,000 |
| Export share (APIs) | Over 90% to 40+ countries/regions |
| R&D locations | Beijing, Shanghai, Nanjing (plus corporate R&D in Yantai) |
- R&D centers focus on process chemistry for APIs, formulation development, and niche radiopharmaceutical technologies.
- Competitive strengths: large-scale API manufacturing, high export penetration, vertical integration into finished drugs and health products.
- Strategic risks: regulatory compliance across export markets, raw-material price volatility, and competition from other large API producers.
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ): History
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) was founded in the late 20th century in Yantai, Shandong Province, growing from a regional pharmaceutical manufacturer into a diversified pharmaceutical group focused on cardiovascular, metabolic, and digestive system therapies. The company completed its Shenzhen Stock Exchange listing under ticker 002675, enabling access to public capital and expanding R&D and production capacity.- Public listing: Shenzhen Stock Exchange (002675.SZ)
- Primary business lines: finished dosage formulations, active pharmaceutical ingredients (APIs), and contract manufacturing
- Geographic footprint: domestic China distribution with growing export activities to Asia-Pacific markets
- Share listing: Publicly traded on SZSE (002675)
- Shareholder mix: institutional investors, retail/individual shareholders, and company insiders (management & founders)
- Investor profile: combination of long-term strategic holders and active short-term traders
- Governance: board of directors, supervisory board, and executive management overseeing strategy, compliance, and operations
| Metric | Value |
|---|---|
| Market capitalization (Dec 2025, CNY) | 11.89 billion |
| Average daily trading volume (shares) | > 11 million |
| Listed ticker | 002675.SZ |
| Primary revenue drivers | Finished drugs, APIs, contract manufacturing |
| R&D investment (most recent fiscal year, % of revenue) | ~5-8% (company target range) |
- Deliver safe, effective, and affordable medicines for chronic diseases (cardiovascular, metabolic, gastrointestinal)
- Invest in R&D and manufacturing quality to meet domestic and international regulatory standards
- Create long-term shareholder value while maintaining compliance and social responsibility
- Manufacturing: operates production lines for oral solids, APIs, and sterile preparations-selling both branded generics and contract-manufactured products
- Sales channels: hospital procurement, pharmacy chains, distributors, and exports
- R&D to commercial pipeline: in-house formulation development and process optimization reduce COGS and enable product margin expansion
- Pricing and reimbursement: revenue influenced by national procurement, regional hospital tenders, and inclusion in NRDL/insurance formularies
| Revenue Component | Description | Typical Margin Profile |
|---|---|---|
| Finished pharmaceuticals | Branded generics and prescription products sold domestically | Gross margin: 30-45% |
| APIs | Bulk API production for internal use and external sales | Gross margin: 15-30% |
| Contract manufacturing (CMO) | Third-party production, formulation, and packaging services | Gross margin: 10-25% |
| Exports & partnerships | Overseas distribution agreements, licensing deals | Variable; strategic value to growth |
- Market cap (Dec 2025): ~11.89 billion CNY - indicates mid-cap positioning within Chinese pharma
- Liquidity: daily trading volume >11 million shares - strong market interest and tradability
- Investor mix: institutional ownership provides stability; active retail trading contributes to short-term volatility
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ): Ownership Structure
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) operates under the guiding mission 'Base in Orient, Commitment to Health,' prioritizing health, innovation, quality and global reach. The company invests heavily in R&D - approximately 8%-10% of annual revenue - while holding multiple international GMP certifications and exporting products to over 40 countries and regions.- Mission: 'Base in Orient, Commitment to Health' - focus on public health, preventive medicine and accessible therapeutics.
- R&D investment: ~8%-10% of revenue annually (targeting new formulations, biologics and delivery technologies).
- Quality certifications: GMP approvals including Korea Food & Drug Administration and European Directorate for the Quality of Medicines.
- Global footprint: exports to 40+ countries across Europe, the Americas and Asia Pacific.
- Sustainability: initiatives to reduce waste and energy consumption in production lines and packaging.
- Collaboration: strategic alliances with international pharma partners for co-development and distribution.
| Metric | 2022 (Approx.) | 2023 (Approx.) |
|---|---|---|
| Total Revenue (RMB) | 2.45 billion | 2.80 billion |
| Net Profit (RMB) | 190 million | 220 million |
| R&D Expense (% of Revenue) | ~8% | ~9% |
| R&D Spend (RMB) | 196 million | 252 million |
| Export Coverage | Products exported to 40+ countries (Europe, Americas, Asia Pacific) | |
| Employees | ~4,200 | ~4,500 |
- Ownership composition: a mix of institutional investors, domestic strategic shareholders and public float on the Shenzhen Stock Exchange (002675.SZ), with major blockholders typically comprising founding group entities and strategic partners.
- Revenue streams: pharmaceutical API and finished dosage forms, OTC consumer health products, contract manufacturing and overseas distribution channels.
- Value drivers: continued R&D pipeline, international GMP compliance, expansion of export markets, and operational sustainability measures that lower manufacturing costs.
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ): Mission and Values
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) operates as a vertically integrated pharmaceutical enterprise combining research and development, manufacturing, and global sales. Its core mission emphasizes delivering safe, high-quality pharmaceuticals and nuclear medicine solutions while advancing healthcare through innovation and international collaboration.- Vertically integrated model: R&D → GMP-compliant manufacturing → domestic & international sales.
- Commitment to regulatory compliance: multiple facilities certified to meet global GMP and relevant international standards.
- Innovation-driven: targets R&D investment of approximately 8%-10% of total revenue annually.
- Export-focused commercial strategy: exports exceed 90% of production to more than 40 countries and regions.
- Research & Development: internal discovery and formulation teams plus collaborations with academic and clinical partners, with focused pipelines in biochemical APIs, radiopharmaceuticals (nuclide drugs), finished dosage forms, and health products.
- Manufacturing: multiple state-of-the-art plants operating under strict GMP, specialized production lines for APIs, sterile injectables and radiopharmaceutical preparations, and separate cleanrooms for nuclide handling.
- Quality & regulatory: centralized QA/QC labs, batch release protocols, and regulatory affairs teams managing registrations across Asia, Europe, and other export markets.
- Sales & distribution: a global sales network and channel partners; direct subsidiaries and local distributors in key regions to support market access and after-sales technical services.
- Subsidiaries & branches: dedicated entities for production, sales, equipment supply, technology research, and nuclear medicine consulting across multiple Chinese cities.
- Biochemical active pharmaceutical ingredients (APIs)
- Finished dosage forms (oral, injectable)
- Nuclide/radiopharmaceutical drugs and kits
- Health products and medical consumables
| Metric | Value / Notes |
|---|---|
| R&D spend (% of revenue) | Approximately 8%-10% annually |
| Export share | Over 90% of products exported |
| International reach | Products sold in >40 countries and regions |
| Facility certifications | Multiple GMP-certified sites (domestic & export-oriented) |
| Business segments | APIs, finished dosage forms, nuclide drugs, health products, equipment & services |
| Subsidiaries / branches | Several across China focused on production, sales, equipment supply, R&D and consulting |
- API manufacturing and supply contracts (bulk sales to pharmaceutical manufacturers and distributors)
- Finished dosage and sterile products sold to hospitals, clinics and distributors (domestic & export)
- Radiopharmaceuticals and nuclide drug kits supplied to nuclear medicine centers and hospitals
- Equipment, technical services and consulting for nuclear medicine installations
- Licensing, contract manufacturing (CMO) services and strategic partnerships
- Vertical integration reduces margin leakage between stages (R&D → manufacturing → sales).
- High export orientation diversifies market risk and captures higher-margin international demand.
- Continual R&D reinvestment (8%-10% of revenue) supports pipeline refresh and new product approvals.
- Specialization in radiopharmaceuticals creates niche expertise and technical barriers to entry.
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ): How It Works
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) operates as an integrated biochemical pharmaceutical manufacturer and global supplier, combining raw-material extraction, active pharmaceutical ingredient (API) manufacture, finished-dosage formulation, and specialty/health product development. Its vertically integrated heparin full industry chain-from raw material sourcing through purification, quality control, and finished product-supports traceability, regulatory compliance and margin capture across the value chain.- Primary revenue drivers: biochemical APIs, finished dosage forms, nuclide drugs, and health/nutrition products.
- Global reach: exports account for over 90% of sales to more than 40 countries and regions across Europe, the Americas and Asia Pacific.
- Product breadth: portfolio includes heparin, chondroitin sulfate, glucosamine, collagen, hyaluronic acid, cytochrome C and other biochemical intermediates and health ingredients.
- Strategic partnerships: long-term supply relationships with international pharmaceutical firms provide recurring revenue and help stabilize order flow and pricing.
- Upstream sourcing and control: owning and operating the full heparin chain reduces input volatility and increases gross margin on heparin-derived products.
- API manufacturing: large-scale biochemical API production sold in bulk to global drug manufacturers and contract development/production organizations (CDMOs).
- Finished dosage production: formulation and packaging for select therapeutic indications, capturing higher value than raw APIs.
- Specialty and health products: branded and bulk health-ingredient sales (e.g., glucosamine, collagen, hyaluronic acid) to nutraceutical and cosmetics customers.
- Export-driven sales network: diversified geographic mix (Europe, North & South America, Asia Pacific) reduces single-market risk and supports volume-based pricing.
| Metric | Reported / Company Stated Figure |
|---|---|
| Stock code | 002675.SZ |
| Export proportion of sales | Over 90% |
| Export footprint | More than 40 countries and regions |
| Core product categories | Heparin, chondroitin sulfate, glucosamine, collagen, hyaluronic acid, cytochrome C, nuclide drugs, finished dosage forms, health products |
| Supply-chain advantage | Vertically integrated heparin full industry chain (raw → API → finished) |
| Customer relationships | Long-term stable cooperation with multiple international pharmaceutical enterprises |
- High-margin API exports: bulk biochemical APIs-especially heparin derivatives-constitute a major share of revenue due to scale and specialized manufacturing capabilities.
- Value capture via downstream products: finished dosage forms and branded health products contribute higher per-unit margins and recurring sales through channel partners.
- Geographic diversification: selling to 40+ countries smooths demand cycles and enables volume-driven manufacturing efficiencies.
- Long-term contracts with multinational firms: reduce sales volatility and support predictable utilization of manufacturing capacity.
- Direct bulk/API sales to international pharmaceutical manufacturers and CDMOs.
- Finished dosage and health-product distribution via regional partners and specialized distributors in Europe, the Americas and Asia Pacific.
- OEM/contract manufacturing agreements for specialty ingredients and formulation work.
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ): How It Makes Money
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) monetizes its position as a leading biochemical API and raw material supplier through diversified product lines, integrated industrial control of supply chains, and global distribution channels. The company combines bulk production, specialty APIs, and higher-margin finished intermediates for both pharmaceutical and healthcare sectors.- Core revenue drivers: heparin and heparin-derived APIs, chondroitin sulfate, glucosamine, collagen, hyaluronic acid, and cytochrome C.
- Geographic mix: domestic sales to Chinese pharmaceutical manufacturers and exports to >40 countries across Europe, the Americas and Asia Pacific.
- Vertical integration: upstream raw-material processing through downstream API purification and formulation support, enabling cost control and traceability.
| Metric / Year | 2021 (CNY) | 2022 (CNY) | 2023 (CNY est.) |
|---|---|---|---|
| Total revenue | 2.4 billion | 2.8 billion | 3.1 billion |
| Net profit | 250 million | 300 million | 330 million |
| Export share of revenue | ~28% | ~30% | ~32% |
| Domestic heparin market share | ~12% | ~15% | ~16-18% |
| R&D spend | 110 million | 130 million | 150 million |
- APIs and intermediates (heparin, chondroitin sulfate, glucosamine): ~60-65% of revenue.
- Biopolymer products (collagen, hyaluronic acid): ~20% of revenue, higher growth rate due to cosmetics & medical device demand.
- Specialty proteins (cytochrome C) and other biochemical reagents: ~10-15% of revenue, higher margins.
- Significant domestic footprint as a leading biochemical API producer with a concentrated share in heparin and related antithrombotic APIs.
- Stable long-term supply agreements with international pharmaceutical firms, reducing sales volatility and enhancing price negotiation power.
- Fully integrated heparin industry chain-from raw material procurement and quality control to API production and export compliance-ensuring traceability and GMP compliance.
- Export network covering 40+ countries and regions, supporting foreign-currency revenue and diversification.
- Economies of scale in bulk API production lower unit costs; vertical integration reduces input volatility for heparin feedstock.
- R&D-led upgrades shift product mix toward higher-value biochemical and specialty APIs (R&D spend rose from ~110M CNY in 2021 to ~150M CNY in 2023).
- Quality certifications and long-term partnerships with multinational pharmaceutical companies enable premium pricing for traceable, GMP-grade APIs.
- Expected revenue CAGR in the low-to-mid teens over next 3-5 years driven by export growth and higher-margin biotech products.
- Continued investment in R&D and capacity expansion for hyaluronic acid, collagen and specialty proteins to capture cosmetic and regenerative-medicine demand.
- Regulatory and supply-chain resilience from the vertical heparin chain provides competitive insulation against raw-material shocks.
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.